Archive · 20 Jan 2026
Systematix Upgrades Zydus Lifesciences to Buy
Systematix, a brokerage firm, has upgraded the stock of Zydus Lifesciences to 'Buy'.
They think this is a good investment because Zydus got approval from the USFDA for a new drug called Zycubo.
This drug treats a rare disease called Menkes disease.
The approval is important because it could make Zydus' US-based subsidiary, Sentynl Therapeutics, profitable in a few years.
Systematix believes the drug will sell well and make a lot of money, which could make the stock price go up by about 17.8%.
Systematix upgraded Zydus Lifesciences to 'Buy' due to USFDA approval for Zycubo.
Zycubo is the first approved treatment for Menkes disease, a rare condition with low survival rates.
The drug is expected to make Sentynl Therapeutics profitable by FY28.
Projected sales for Zycubo are USD 10-15 million in FY28, rising to USD 50 million by FY30.
Systematix set a target price of Rs 1,038 for Zydus Lifesciences, implying a 17.8% upside.
- Who
- Systematix Institutional Equities
- What
- Upgraded Zydus Lifesciences to 'Buy'
- When
- Recent
- Where
- United States (USFDA approval)
- Why
- USFDA approval for Zycubo, a drug for Menkes disease, expected to boost profitability
- Company
- Zydus Lifesciences
- Brokerage
- Systematix Institutional Equities
- Rating
- Buy
- Target Price
- Rs 1,038
- Current Stock Price
- Rs 881
- Potential Upside
- 17.8%
- Drug Approved
- Zycubo (Copper Histidinate)
- Condition Treated
- Menkes Disease
- Projected FY28 Sales
- USD 10-15 million
- Projected Peak Sales
- USD 50 million by FY30